RecruitingNCT06498128

Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®

QUVIVIQ® Pregnancy Registry

Sponsor

Idorsia Pharmaceuticals Ltd.

Enrollment

785 participants

Start Date

Nov 21, 2024

Study Type

OBSERVATIONAL

Conditions

Insomnia

Summary

This study will investigate pregnancy, neonatal, and infant outcomes in women exposed to QUVIVIQ during pregnancy compared to women unexposed to QUVIVIQ during pregnancy.

Eligibility

Sex: FEMALEMin Age: 15 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Daridorexant, No insomnia medication, and others for people with insomnia. The study is currently recruiting participants at 7 locations. People eligible for this study include women aged 15 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDaridorexant

Dosing and treatment duration of QUVIVIQ as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.

DRUGNon-orexin receptor antagonist medications for insomnia

Dosing and treatment duration of non-orexin receptor antagonist medications for insomnia as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.

OTHERNo insomnia medication

No insomnia medication was administered.